Magdalene K. Sgagias

Array ( [id] => 17412751 [patent_doc_number] => 20220047655 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => AAV-MEDIATED GENE TRANSFER FOR RETINOPATHY [patent_app_type] => utility [patent_app_number] => 17/379997 [patent_app_country] => US [patent_app_date] => 2021-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43024 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17379997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570640 [patent_doc_number] => 20210009646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => VGLL4 WITH UCP-1 CIS-REGULATORY ELEMENT AND METHOD OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/925632 [patent_app_country] => US [patent_app_date] => 2020-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12609 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16925632 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17330218 [patent_doc_number] => 11220671 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-11 [patent_title] => Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ECM, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds [patent_app_type] => utility [patent_app_number] => 16/797945 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 42 [patent_no_of_words] => 46178 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 190 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16797945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16073097 [patent_doc_number] => 20200190535 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => ADULT STEM CELL LINE INTRODUCED WITH HEPATOCYTE GROWTH FACTOR GENE AND NEUROGENIC TRANSCRIPTION FACTOR GENE WITH BASIC HELIX-LOOP-HELIX MOTIF AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/688434 [patent_app_country] => US [patent_app_date] => 2019-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16688434 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16817003 [patent_doc_number] => 11001810 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-05-11 [patent_title] => Serum-free human pluripotent stem cell culture medium [patent_app_type] => utility [patent_app_number] => 16/679932 [patent_app_country] => US [patent_app_date] => 2019-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 8365 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16679932 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17451296 [patent_doc_number] => 11266129 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => Murine model of fetal/neonatal alloimmune thrombocytopenia [patent_app_type] => utility [patent_app_number] => 16/674804 [patent_app_country] => US [patent_app_date] => 2019-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 15317 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16674804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17860036 [patent_doc_number] => 11441184 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Method for generating retinal pigment epithelium (RPE) cells from induced pluripotent stem cells (IPSCs) [patent_app_type] => utility [patent_app_number] => 16/586656 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 68 [patent_no_of_words] => 36208 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 289 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16586656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15408503 [patent_doc_number] => 20200024573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => CHEMICAL DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO RETINAL EPITHELIAL CELLS [patent_app_type] => utility [patent_app_number] => 16/571875 [patent_app_country] => US [patent_app_date] => 2019-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6249 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16571875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16326822 [patent_doc_number] => 20200297787 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => APMV AND USES THEREOF FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/645378 [patent_app_country] => US [patent_app_date] => 2019-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51319 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15112931 [patent_doc_number] => 20190343098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD40 [patent_app_type] => utility [patent_app_number] => 16/435453 [patent_app_country] => US [patent_app_date] => 2019-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22559 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16435453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14864721 [patent_doc_number] => 20190282602 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => METHOD FOR PRODUCING FOUNDER ANIMAL FOR REPRODUCING ANIMAL HAVING LETHAL PHENOTYPE CAUSED BY GENE MODIFICATION [patent_app_type] => utility [patent_app_number] => 16/363152 [patent_app_country] => US [patent_app_date] => 2019-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20059 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16363152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14868027 [patent_doc_number] => 20190284255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => PROGRAMMABLE IMMUNOCYTE RECEPTOR COMPLEX SYSTEM [patent_app_type] => utility [patent_app_number] => 16/353337 [patent_app_country] => US [patent_app_date] => 2019-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16353337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14280395 [patent_doc_number] => 20190137482 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => HIGH THROUGHPUT SCREENING OF AGENTS ON DOPAMINERGIC NEURONS [patent_app_type] => utility [patent_app_number] => 16/242023 [patent_app_country] => US [patent_app_date] => 2019-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9860 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16242023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14277797 [patent_doc_number] => 20190136183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => TREATMENT OF CNS DISORDERS USING DESCENDANTS OF MSCS EXPRESSING AN EXOGENOUS NOTCH INTRACELLULAR DOMAIN [patent_app_type] => utility [patent_app_number] => 16/241802 [patent_app_country] => US [patent_app_date] => 2019-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12652 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16241802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14930425 [patent_doc_number] => 20190300850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => Compositions and Methods for Autologous Germline Mitochondrial Energy Transfer [patent_app_type] => utility [patent_app_number] => 16/230839 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20939 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16230839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14582037 [patent_doc_number] => 20190218627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSID AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/230080 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17450 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16230080 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15254721 [patent_doc_number] => 20190376094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE [patent_app_type] => utility [patent_app_number] => 16/191096 [patent_app_country] => US [patent_app_date] => 2018-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53520 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16191096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17587927 [patent_doc_number] => 11326185 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-10 [patent_title] => Site-specific integration [patent_app_type] => utility [patent_app_number] => 16/176525 [patent_app_country] => US [patent_app_date] => 2018-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 14333 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16176525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14182951 [patent_doc_number] => 20190111180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => Tissue Products Derived from Animals Lacking any Expression of Functional Alpha 1, 3 Galactosyltransferase [patent_app_type] => utility [patent_app_number] => 16/169180 [patent_app_country] => US [patent_app_date] => 2018-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35282 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16169180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13867697 [patent_doc_number] => 20190030189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => DELIVERY OF POLYNUCLEOTIDES USING RECOMBINANT AAV9 [patent_app_type] => utility [patent_app_number] => 16/159986 [patent_app_country] => US [patent_app_date] => 2018-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16159986 [rel_patent_id] =>[rel_patent_doc_number] =>)